AptarGroup Q4 2022 Earnings Report
Key Takeaways
AptarGroup's Q4 2022 results showed a mixed performance, with net income increasing by 2% but reported sales decreasing by 2%. Core sales, excluding currency and acquisition effects, increased by 4%. The company saw strong volume growth in its consumer healthcare and prescription divisions, as well as in beauty dispensing solutions for prestige fragrance and skincare.
Reported sales decreased 2% and net income increased 2% to $59 million.
Core sales increased 4% and adjusted EBITDA of $147 million decreased 4% from the prior year.
Reported earnings per share increased 5% to $0.89 compared to $0.85 in the prior year.
Adjusted earnings per share increased 5% to $0.92 compared to $0.88 in the prior year (including comparable exchange rates).
AptarGroup
AptarGroup
AptarGroup Revenue by Segment
Forward Guidance
Aptar expects earnings per share for the first quarter of 2023, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $0.85 to $0.93.
Positive Outlook
- We expect the momentum to continue in Pharma, especially for prescription and consumer healthcare
- Momentum to continue in our beauty end-markets such as fragrance and skincare.
- A key focus in 2023 and beyond will be to continue to leverage our fixed cost base
- Increase efficiencies in 2023
- Increase efficiencies beyond 2023
Revenue & Expenses
Visualization of income flow from segment revenue to net income